1-Naphthohydroxamic acid
(Synonyms: 1-萘羟肟酸) 目录号 : GC39214
1-Naphthohydroxamic acid是强效、细胞渗透性和选择性组蛋白脱乙酰酶抑制剂 (HDAC8) 抑制剂（IC?50?= 14 μM）。在体外有抗癌活性。
Cas No.:6953-61-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
1-Naphthohydroxamic acid (Compound 2) is a potent and selective HDAC8 inhibitor with an IC50 of 14 μM. 1-Naphthohydroxamic acid is more selectively for HDAC8 than class I HDAC1 and class II HDAC6 (IC50 >100 μM). 1-Naphthohydroxamic acid does not increase global histone H4 acetylation and also does not reduce total intracellular HDAC activity[1][2].1-Naphthohydroxamic acid can induce tubulin acetylation[3].
[1]. Krennhrubec K, et al. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2874-8. [2]. Oehme I, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res. 2009 Jan 1;15(1):91-9.
| Cas No. | 6953-61-3 | SDF | |
| 别名 | 1-萘羟肟酸 | ||
| Canonical SMILES | O=C(C1=C2C=CC=CC2=CC=C1)NO | ||
| 分子式 | C11H9NO2 | 分子量 | 187.19 |
| 溶解度 | DMSO: 125 mg/mL (667.77 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.3422 mL | 26.7108 mL | 53.4217 mL |
| 5 mM | 1.0684 mL | 5.3422 mL | 10.6843 mL |
| 10 mM | 0.5342 mL | 2.6711 mL | 5.3422 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Utilization of Fe3+ by the inshore colorless marine dinoflagellate Crypthecodinium cohnii
Ann N Y Acad Sci 1975 Jan 24;245:16-25.PMID:242248DOI:10.1111/j.1749-6632.1975.tb26828.x
A Puerto Rican isolate of the colorless dinoflagellate Crypthecodinium cohnii was grown in a defined marine medium. Fe was added as Fe(NH4)2(SO3)2 - 6H2O (2.0 mg%), FeCl3 - 6H2O (1.0 mg%) or a particulate slurry prepared from FeCl3 + KOH, along with varying concentrations of several chelators. Heavy growth at pH 7.5-7.7 occurred with salicylhydroxamic acid, aurintricarboxylic acid, EDTA, NTA, and humic acid; and at pH 7.9-8.1 with SHAM and ATA. Moderate growth occurred at pH 7.5-7.7 with sulfosalicylic acid, dipicolinic acid, pyrocatecholdisulfonic acid, hexanohydroxamic acid, L-histidine, and at pH 7.9-8.1 with 1-Naphthohydroxamic acid, EDTA, NTA. Slight growth occurred at pH 7.5-7.7 with benzohydroxamic acid, 1-naphohydroxamic acid, 2.6-dipicolinic acid N-oxide, salicylic acid, rhodotorulic acid, Na oxalate, EDDHA, sorbohydroxamic acid, gamma-pyrone-2, 6-decarboxylic acid, and at pH 7.9-8.1 with hexanohydroxamic acid, benzohydroxamic acid. Some ecological and physiological implications are discussed.